Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

Business Wire • Aug 11, 2026

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. (“Purchaser”), a wholly-owned subsidiary of argenx BV (“argenx”), has commenced a tender offer to purchase all of the issued and outstanding shares of Common Stock, par value $0.001 per share (the “Shares”), of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX), for $77.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 6, 2026, and the accompanying Letter of Transmittal (together, and with other related materials, as they may be amended or supplemented from time to time, the “Offer”). The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of July 26, 2026, by and among Forte, argenx and Purchaser (the “Merger Agreement”).

GlobeNewsWire • Aug 6, 2026

What Makes Argenx (ARGX) a New Buy Stock

Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 4, 2026

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands. The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend.

GlobeNewsWire • Aug 3, 2026

A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors

Investors are becoming more open to international equities after years of U.S.-heavy portfolios, Janus Henderson Investors' Julian McManus told CNBC. McManus said "Magnificent Seven" concentration has left portfolios vulnerable.

CNBC • Jul 31, 2026

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jul 31, 2026

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 29, 2026

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

I upgrade argenx to BUY with a $1,050 price target, citing sustained VYVGART growth, label expansion, and a strong balance sheet. VYVGART's commercial momentum is robust, with expanded indications, at-home administration, and a growing prescriber base supporting long-term growth. Pipeline optionality, notably empasiprubart and autoimmune myositis, provides meaningful upside not fully reflected in ARGX's current valuation.

Seeking Alpha • Jul 29, 2026

Argenx to buy Forte Biosciences for about $2.2 billion

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune drug ​FB102 to its portfolio, ⁠the company ​said on ​Monday.

Reuters • Jul 27, 2026

argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102

argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease.

MarketBeat • Jul 27, 2026